Latest news with #cancerdetection
Globe and Mail
5 days ago
- Business
- Globe and Mail
Why Guardant Health Stock Surged Nearly 9% Higher Today
Precision oncology specialist Guardant Health (NASDAQ: GH) was something of a stock market star on Tuesday. On the back of very positive news in the regulatory sphere, the company's shares jumped almost 9% higher today. This made it quite the outperformer on the exchange, as the bellwether S&P 500 index's gain was a relatively modest 0.6%. A new designation This morning before market open, Guardant announced that the U.S. Food and Drug Administration (FDA) had granted the healthcare company's Shield multi-cancer detection (MCD) test its Breakthrough Device designation. This instantly confers a high status on Shield, as the FDA's designation is given only to a small clutch of medical devices that can either diagnose or treat a disease more effectively than other products. In Shield's case, it is quite a versatile diagnostic device that can screen for a wide range of cancers, including colorectal, lung, and ovarian. It is designed to evaluate people 45 years of age or older who are at a typical average risk for cancer. According to Guardant, Shield has 98.6% specificity and 75% sensitivity in detecting certain cancers. In its news release touting the FDA's move, Guardant quoted its co-CEO AmirAli Talasaz as saying that it "shows the promise of the Shield MCD test to detect multiple cancers at an early stage with just a single, routine blood draw." "We look forward to partnering with the agency and other stakeholders to bring this breakthrough to patients quickly," he added. Coming to market soon Another big plus of the Breakthrough Device designation is that it's part of an FDA initiative aimed at getting useful medical products to market faster. Talasaz and his team at Guardant might just get their wish with Shield before long. Should you invest $1,000 in Guardant Health right now? Before you buy stock in Guardant Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Guardant Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $657,385!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $842,015!* Now, it's worth noting Stock Advisor 's total average return is987% — a market-crushing outperformance compared to171%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
Yahoo
10-05-2025
- Business
- Yahoo
Elizabeth Holmes' partner reportedly fundraising for new blood-testing startup
Billy Evans, partner of Theranos founder Elizabeth Holmes, is working on a new startup that seeks to deliver 'human health optimization' through blood testing, according to The New York Times. The Times reportedly spoke to two investors pitched on the startup, called Haemanthus, and also viewed some of Haemanthus' marketing materials. In those materials, the company says it has developed a machine that uses lasers to analyze blood, saliva, and urine samples to detect cancer and infections. It reportedly plans to start with pet health before expanding to humans, and it seeks to raise more than $50 million. The pitch echoes that for Theranos, which promised to conduct a variety of medical tests on tiny amounts of blood drawn from pricked fingers. In 2022, Holmes (with whom Evans has two children) was sentenced to 11 years in prison for defrauding investors, though she said in a recent interview that she remains 'completely committed to my dream of making affordable healthcare solutions available to everyone.' Early Facebook investor Jim Breyer told The Times that his team was asked to invest but declined 'for many of the same reasons we passed twice on Theranos.' Error while retrieving data Sign in to access your portfolio Error while retrieving data
